Author: Jamal, Muhammad; Bangash, Hina Iqbal; Habiba, Maria; Lei, Yufei; Xie, Tian; Sun, Jiaxing; Wei, Zimeng; Hong, Zixi; Shao, Liang; Zhang, Qiuping
Title: Immune dysregulation and system pathology in COVID-19 Cord-id: x7lrtw75 Document date: 2021_3_23
ID: x7lrtw75
Snippet: The coronavirus disease 19 (COVID-19) caused by the novel coronavirus known as SARS-CoV-2 has caused a global public health crisis. As of 7 January 2021, 87,640,402 confirmed cases and 1,891,692 mortalities have been reported worldwide. Studies focusing on the epidemiological and clinical characteristics of COVID-19 patients have suggested a dysregulated immune response characterized by lymphopenia and cytokine storm in these patients. The exaggerated immune response induced by the cytokine stor
Document: The coronavirus disease 19 (COVID-19) caused by the novel coronavirus known as SARS-CoV-2 has caused a global public health crisis. As of 7 January 2021, 87,640,402 confirmed cases and 1,891,692 mortalities have been reported worldwide. Studies focusing on the epidemiological and clinical characteristics of COVID-19 patients have suggested a dysregulated immune response characterized by lymphopenia and cytokine storm in these patients. The exaggerated immune response induced by the cytokine storm causes septic shock, acute respiratory distress syndrome (ARDS), and/or multiple organs failure, which increases the fatality rate of patients with SARS-CoV-2 infection. Herein, we review the recent research progress on epidemiology, clinical features, and system pathology in COVID-19. Moreover, we summarized the recent therapeutic strategies, which are either approved, under clinical trial, and/or under investigation by the local or global health authorities. We assume that treatments should focus on the use of antiviral drugs in combination with immunomodulators as well as treatment of the underlying comorbidities.
Search related documents:
Co phrase search for related documents- abdominal pain and activation role: 1, 2
- abdominal pain and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- abdominal pain and acute patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- abdominal pain and acute phase protein: 1
- abdominal pain and acute phase protein increase: 1
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and adalimumab anti: 1
- abdominal pain and admission time: 1, 2, 3, 4, 5, 6, 7
- abdominal pain and liver damage: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and liver dysfunction: 1, 2, 3, 4
- abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abdominal pain and local inflammation: 1, 2
- abdominal pain and low proportion: 1
- abdominal pain and lung injury: 1, 2, 3, 4, 5
- abdominal pain and lung tissue: 1, 2
- abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7
- abdominal pain and lymphocyte neutrophil ratio: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date